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A pandemic caused by the novel coronavirus, severe acute respiratory
syndrome - coronavirus 2 (SARS-CoV-2), has caused high rates of
mortality, predominantly in adults. Children are significantly less
affected by SARS-CoV-2 with far lower rates of recorded infections
in children compared to adults, milder symptoms in the majority of
children and very low mortality rates. A suspected late manifestation
of the disease, paediatric inflammatory multisystem syndrome -
temporally associated with SARS-CoV-2 (PIMS-TS), has been seen
in small numbers of children and has a more severe disease course
than acute SARS-CoV-2. The pandemic has meant that children
around the world have been kept off school, isolated from their
extended family and friends and asked to stay inside. The UK has
been declared as being in an economic recession and unemployment
rates are increasing. These indirect effects of SARS-CoV-2 are likely to
have a significant impact on many children for years to come. Consol-
idating the knowledge that has accumulated during the first wave of
this pandemic is essential for recognising the clinical signs, symptoms
and effective treatment strategies for children; identifying children who
may be at increased risk of severe SARS-CoV-2 infection; planning the
safe delivery of healthcare and non-health related services that are
important for childrens’ wellbeing; and engaging in, and developing,
research to address the things that are not yet known. This article
summarises the evidence that has emerged from the early phase of
the pandemic and offers an overview for those looking after children
or planning services.
Keywords acute respiratory distress syndrome; children; COVID-19;
PIMS-TS; viral transmission
Introduction
Severe Acute Respiratory Syndrome - Coronavirus 2 (SARS-CoV-2)
has, up to the 10th Aug, 2020, caused nearly 19.6 million infections
and 727,000 deaths worldwide.1 This impact has largely been on
adults. But what of children? Although not the face of the COVID-
19 pandemic, they have been an important part of the story. Now
is the time to consider what was learnt during the first wave, to
prepare for any future wave(s) and to ensure that children are
prioritised in this "new normal" as soon and safely as possible.
With this in mind, we aim to discuss evidence, dilemmas, and
theories, around COVID-19 in children.
What is the SARS-CoV2 virus, and how does it cause
infections?
SARS-CoV-2 is a novel coronavirus, first isolated from patients
with pneumonia in Wuhan, China, in late 2019. Of hundreds of
coronaviruses, only seven are known to cause disease in
humans; four seasonal coronaviruses (NL63, HKU1, OC43 and
E229), Severe Acute Respiratory Syndrome (SARS-CoV), Middle
East Respiratory Syndrome (MERS), and SARS-CoV-2. SARS-
CoV-2 is carried in the respiratory tract of infected people and
spread during speech and coughing. In droplet form, the virus
remains viable and infectious for several hours.2 Transmission
occurs through either aerosol inhalation or transfer from a
contaminated surface to the mouth. In order to develop anPAEDIATRICS AND CHILD HEALTH xxx:xxx 2
Please cite this article as: Bogiatzopoulou A et al., COVID-19 in children:
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we think of the infection as a bonfire, the infectious dose (the
number of particles needed to start an infection) is the size of the
spark needed to light the fire and the subsequent viral load (the
amount of virus that someone is carrying) is how big the bonfire
(or severe the infection) is.
Coronaviruses take their name from spikes covering their
surface, which aid entry into host cells. Using these spike-
proteins, SARS-CoV-2 are thought to interact with Angiotensin
Converting Enzyme 2 receptors (ACE2-r), expressed on the outer
membrane of host cells in various tissues, particularly alveolar
epithelial cells, the endothelium and the intestinal epithelium.3 It
is unclear what role, if any, the levels of soluble ACE2 play in
host susceptibility to coronaviruses, and if ACE2 represents the
only cell receptor used by SARS-CoV2.
Why does COVID-19 affect children less than adults?
Worldwide, children constitute only 2% of recorded infections.4,5
When children have had contact with people infected with
COVID-19 they are probably less likely to contract the infection
compared to adults.6e8 Furthermore, they are far less likely to
develop clinical symptoms, and severe illness is rare.9,10 It is not
yet clear why this is the case, particularly when viral respiratory
illnesses typically affect children more commonly than healthy
adults and Influenza virus is associated with a more severe
course in young children.11 The replication dynamics of SARS-
CoV-2 are poorly described, but viral load in symptomatic pa-
tients is very high, and is higher in older patients,12 which may in
part account for the disease severity in the elderly. Children are
also likely to have other viruses in their upper respiratory tract,
and interactions and competition with SARS-CoV-2 may dampen
its ability to cause infection.13
ACE2-r may hold some of the answers. Like SARS-CoV-2, SARS-
CoV uses the ACE2-r to enter cells and it has been shown that un-
differentiated cells (which express lower levels of the ACE2-r) are
less likely to be infectedwith the virus.14 Childrenhave significantly
lower levels of ACE2-r than adults in their nasal epithelium,15 and
this may make them less susceptible to infection.
The immune system varies with age,16 both in its composition
and response to viruses. It is likely that the immune systems of
babies, older children, and adults differ in response to SARS-
CoV-2. Some differences might reflect the ability to protect
against the virus, whereas others might relate to the more
harmful effects of the immune response to infection. Previous
exposure to seasonal coronavirus may also provide a level of
protection through cross-reactive T-cell epitopes against SARS-
CoV-2.17
How do you test for COVID-19?
Testing for COVID-19 can assess for either acute or previous
infection, to detect early and late manifestations of the disease. For
acute infection, reverse transcriptase polymerase chain reaction
(RT-PCR) is used, and is most accurate when performed on a
nasopharyngeal sample. Factors that affect the accuracy of testing
include the quality of sample, stage of disease, and viral load in 2020 Elsevier Ltd. All rights reserved.
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ficity of 95% but a lower sensitivity of approximately 70%.18,19
Detection of recent or previous infection is undertaken using
serological testing for IgG and IgM. Depending on the type and
timing of test, the sensitivity varies from 66% to 97.8%, and the
specificity from 96.6% to 99.7%.20
Knowing whether someone is currently, or has recently been,
infected by COVID-19 is useful, but it does not determine
whether someone who tests positive is shedding live virus.
Whilst viral replication stops 5e7 days after the onset of symp-
toms, patients can remain RNA-positive for up to a fortnight af-
terwards.21 The results of the tests should therefore be taken
within the context of the patient’s presenting features and the
community prevalence of COVID-19.
What are the clinical, laboratory and radiological features
of acute COVID-19 in children?
The commonest acute presenting features in children with
COVID-19 are fever, cough, lethargy, coryzal symptoms, and
shortness of breath.10 In the International Severe Acute Respi-
ratory and emergency Infections Consortium WHO Clinical
Characterisation Protocol UK (ISARIC WHO CCP-UK) a distinct
cluster of muco-enteric symptoms (including abdominal pain,
vomiting, diarrhoea, conjunctivitis and rash) was noted in the
paediatric population.10 Around 10% of hospitalized children
with COVID-19 have an additional infective diagnosis such as
urinary tract infection, appendicitis and sepsis.22
Laboratory features of acute COVID-19 are variable and a
significant proportion of children have normal investigations.
Lymphopaenia, elevated inflammatory markers including C
Reactive Protein (CRP) and procalcitonin have been documented
but are by no means universal.23,24 Many Chinese children sus-
pected of having COVID-19 underwent Computed Tomography
(CT) of the thorax. The radiological findings of subpleural lesions
were strongly associated with SARS-CoV-2 infection, along with
more general findings consistent with viral infection,25 but per-
forming a CT did not alter the management of the majority of
these children.
When chest radiography has been performed in children with
COVID-19 no specific features have been found to be diagnostic
and therefore the indications for chest X-ray remain as they were
before the pandemic. Children with COVID-19 who have radio-
logical evidence of pneumonia are significantly more likely to
require ICU admission.26How does COVID-19 affect neonates?
Very few neonates have been reported to have COVID-19. The
majority who have been infected have not required intensive
care unit (ICU) admission, although compared to all children, age
under 1 month is a risk factor for ICU admission.26 Limited evi-
dence suggests vertical transmission to neonates, whether in-
trauterine or perinatal, is possible but rare27 and it is thought that
the majority of infected neonates contracted COVID-19 after
birth. Current literature does not suggest that SARS-CoV-2 can be
transmitted through breast milk as no replicable virus has been
identified.28 The World Health Organisation has concluded thatPAEDIATRICS AND CHILD HEALTH xxx:xxx 3
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separated from their infants and that they should be encouraged
to initiate and continue breastfeeding.29Is COVID-19 worse in children with pre-existing medical
conditions?
Over 10% of English children in hospital with COVID-19 were
diagnosed whilst an inpatient.22 This may reflect increased levels
of testing in hospital which can result in a high rate of false
positive tests during periods of low to moderate prevalence and
can detect infection in asymptomatic and pauci-symptomatic
children who are admitted for an unrelated reason. However, it
may also highlight children’s increased susceptibility to infection
during a hospital stay and requires further investigation. A North
American Observational study of 48 children with COVID-19 who
were admitted to ICU found that 86% had pre-existing co-mor-
bidities. These included being medically complex (40%),
immunosuppressed (23%), obese (15%) and diabetic (8%).
Thirty six percent of children in this series required mechanical
ventilation and the association of respiratory support with co-
morbidity is unclear.30
It is likely that families with children with certain co-
morbidities such as cancer have been actively shielding from
an early stage of the pandemic. Early studies do not suggest that
there is increased susceptibility to infection in many groups who
were origionally asked to shield31 but ongoing data collection
about the impact of co-morbidity on the rate and severity of
COVID-19 is needed to better elucidate any associations.Treatment options
Most children with COVID-19 require only supportive therapy,
with less than a quarter of hospitalized children requiring oxygen
and very small numbers requiring ventilatory support.22,26,32
However, a small number of children do become severely un-
well with COVID-19 and require specialist therapies. The thera-
peutic options have been assessed primarily in adult patients
with severe COVID-19 as the numbers of children with severe
COVID-19 are so small.
Adult literature currently shows that the most effective agent
for reducing mortality in critically unwell adults with acute
COVID-19 is dexamethasone.33 This reduces 28 day mortality in
adults requiring oxygen by 20% and in adults requiring venti-
lation by 33%. It shows no benefit in adults who have not
required either of these therapies. Remdesivir, an anti-viral
treatment, has been shown to reduce time to clinical improve-
ment in adults and is available for use in children.34How should respiratory failure from COVID-19 be
managed?
As respiratory compromise is relatively unusual with COVID-19
in children, its presence should trigger consideration of its cause.
 COVID-19 pneumonia leads to patchy areas of consolidation,
which reduce lung capacity.
 High levels of inflammation are damaging to lung paren-
chyma, this inflammation in the longer term could lead to 2020 Elsevier Ltd. All rights reserved.
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tain. 35
 COVID-19 infection is associated with anxiety.36 This can lead
to tachypnoea, which in itself can be damaging to lungs and
causes fatigue of respiratory muscles.
 COVID-19 is a prothrombotic state,37 and in a child with
disproportionately high oxygen requirement, a pulmonary
embolism (or microthrombotic events) should be
considered.
What is PIMS-TS?
PIMS-TS (Paediatric Inflammatory Multisystem Syndrome -
Temporally Associated with SARS-CoV-2) is an emerging
phenotype of illness that has been described in observational
series from the UK, USA, Italy, France and Spain. Although
definitions vary by country, the consistent features are inflam-
mation and organ dysfunction in the absence of another clear
cause. Presentation can overlap with acute COVID-19 illness, or
be a delayed response up to six weeks later.4,7,9
The presentation of PIMS-TS is varied: some children present
acutely unwell with features of shock, others with features
consistent with complete or incomplete Kawasaki Disease, and
others with more non-specific features.38 Definitions, whether
from the UK or US, include the presence of persistent fever at
presentation. Abdominal pain is present in over 50% of children,
along with hand and foot swelling, mucous membrane changes,
non-purulent conjunctivitis, rash and gastrointestinal distur-
bance.38 A proposed list of investigations is presented in Table 1.39
Therapeutic options include intravenous immunoglobulin
(IVIg), methylprednisolone and more targeted immune modula-
tion including Anakinra, Tocilizumab and Infliximab.39e42 InInvestigations for patients with suspected PIMS-TS
Investigations First line diagnostic tests
to determine whether
PIMS-TS is a possible
diagnosis
Second line tests to
differentiate PIMS-TS
from other conditions and
determine severity
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children may develop coronary artery aneurysms, making
follow-up echocardiography essential.39,43
What do we know about COVID-19 in children in Low and
Middle Income Countries?
Little is known about COVID-19 in Low and Middle Income Coun-
tries (LMICs) and issues with testing and reporting of cases has
made tracking the spread and incidence of the disease difficult. At
the timeofwriting, theAfrican continent has reported885,000 cases
and 16,000 deaths with the majority of these in South Africa. India
alone has reported 64,000 new cases in one day.44
The spread and severity of COVID-19 is expected be further
exacerbated in LMICs by crowded living conditions, poor sani-
tation and difficult access to healthcare. The economic impact of
enforced lockdown and social distancing has the potential to
increase violence in areas already experiencing conflict, and
violence against women and girls has been noted to increase
since the beginning of the COVID-19 pandemic.45 Food insecurity
has been highlighted as a key area for concern by the World
Bank.46 It is extremely likely that the negative impact of COVID-
19 on children in LMICs will be much greater than the impact of
the virus itself.47
What is the impact of lockdown on children?
Lockdown causes deficiencies and inequity that may have a long-
term effect on the wellbeing of children. It may particularly impact
learning progress, socialising, friendship, play, romantic re-
lationships andphysical activity. In addition, children in lockdown
experience an increase in both violence and addictive behaviours
(e.g., junk food, alcohol, and other substances), and a decrease in
positive factors related to health promotion (e.g., vaccina-
tion).48,49 Concerns about the well-being of teenagers’ mental
health led to a review of child suicide rates during the pandemic.
Whilst the numbers of deaths due to suicide were not statistically
significantly increased compared to the previous year, themes
around isolation and poor mental health were recognized as
contributing factors for childhood suicide during the pandemic.50
Some have argued there may be potential benefits for certain
groups of children, including more time to share with family and
appreciation of the value of social responsibility for the protec-
tion of the most vulnerable. However, for many, and particularly
the most vulnerable children in our society, the balance of harms
and benefits of a lockdown, and particularly school closure,
clearly points away from this being a positive experience for
many children.
What COVID-19 research is happening in children?
There are several key differences in the way research studies
have been organized and delivered regarding COVID-19 and
paediatrics. In the UK, the National Institute of Health Research
(NIHR) has produced a list of prioritized COVID-19 studies, to
ensure that despite the reallocation of resources to support the
clinical services that were most under stain from the first wave,
there were clear research objectives. 2020 Elsevier Ltd. All rights reserved.
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paediatric population have included the following:
 ISARIC-WHO: A tiered study that collects clinical and bio-
logical data on COVID-19 positive patients. Includes children
and adults.
 BPSU study - Neonatal complications of coronavirus disease
(COVID-19). A national surveillance study of babies born to
mothers with COVID-19 and of neonates who develop
COVID-19.
 DIAMONDS: A biomarker study examining both COVID-19
and other infectious/inflammatory illnesses. Includes chil-
dren and adults.
 PRIEST (recruitment completed): An emergency department
study collecting details of the presentation of suspected
COVID-19 patients to improve triage.
 RECOVERY: An open label, multi-arm platform study, with
randomisation to different treatment arms (or standard of
care). It has evolved to include neonates and children, and
now has a randomisation option for children with PIMS-TS
which includes IVIg, steroids and supportive care in the
first randomisation and Tocilizumab and standard care
(which can include giving Anakinra or Infliximab) in the
second randomisation.
The RECOVERY trial has been one of the most effective trials
within the COVID-19 pandemic internationally. It has shown that
hydroxychloroquine is ineffective51 and that dexamethasone re-
duces mortality for individuals requiring oxygen, and particularly
for ventilated patients.33
Enrolling children whenever possible into trials for both
COVID-19 and PIMS-TS is essential. We have already seen with
both ISARIC and the RECOVERY trial the impact that rapidly
mobilized, actively recruited trials can have on the knowledge
and treatment of a new condition. Adaptations to the RECOVERY
trial now mean that children can be recruited to both phases,
enabling high quality data collection within a trial whilst not
removing the required multi-disciplinary team working that is
essential for decision making about unwell children with severe
acute COVID-19 and PIMS-TS.
Conclusion
The COVID-19 pandemic is predicted to come in waves and the
well-being of children must be prioritized and protected. They
have sacrificed their social and educational development during
the first wave, and going forward the focus must be on safely
but actively returning them to normality. As paediatricians, we
must be alert to cases of PIMS-TS, and other unusual pre-
sentations, and enrol children into appropriate research studies.
Last and not least, we have a duty to keep up to date with
published literature so we can provide care that is as evidence-
based as possible when we are presented with children who
may have COVID-19. A
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